Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Biocardia Inc (BCDA)

Biocardia Inc (BCDA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
BioCardia Announces FDA Approval of IND Application for Allogeneic NK1R+ Human Mesenchymal Stem Cells for Ischemic Heart Failure Business Wire - Tue Dec 6, 2022

BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced Food and Drug Administration (FDA) approval...

BCDA : 2.97 (-0.67%)
BioCardia Reports Second Quarter 2022 Business Highlights And Financial Results Globe Newswire - Wed Aug 10, 2022

SUNNYVALE, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.97 (-0.67%)
BioCardia to Host Q2 2022 Financial Results and Corporate Update Conference Call on August 10, 2022 Globe Newswire - Thu Aug 4, 2022

SUNNYVALE, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.97 (-0.67%)
BioCardia Announces First Canadian Clinical Site for CardiAMP Cell Therapy Heart Failure Trial Globe Newswire - Mon Aug 1, 2022

SUNNYVALE, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.97 (-0.67%)
BioCardia to Participate in Upcoming Heart and Pulmonary Therapy Development Symposia Globe Newswire - Tue Jul 12, 2022

SUNNYVALE, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia®, Inc. [Nasdaq: BCDA], a developer of...

BCDA : 2.97 (-0.67%)
BioCardia Reports First Quarter 2022 Business Highlights and Financial Results Globe Newswire - Wed May 11, 2022

SUNNYVALE, Calif., May 11, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.97 (-0.67%)
BioCardia to Host Q1 2022 Financial Results and Corporate Update Conference Call on May 11, 2022 Globe Newswire - Wed May 4, 2022

SUNNYVALE, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.97 (-0.67%)
BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19 Globe Newswire - Tue Apr 12, 2022

Phase I/II trial initiation expected in 3Q 2022...

BCDA : 2.97 (-0.67%)
BioCardia Reports 2021 Financial Results and Recent Business Highlights Globe Newswire - Tue Mar 29, 2022

SUNNYVALE, Calif., March 29, 2022 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the...

BCDA : 2.97 (-0.67%)
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure Globe Newswire - Tue Mar 22, 2022

New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the CardiAMP Cell Therapy Heart Failure Trial...

BCDA : 2.97 (-0.67%)

Barchart Exclusives

These 3 High-yielding Dividend Aristocrats Are Also Up 10% YTD Barchart - 40 minutes ago
On the hunt for quality companies with positive price performance? These 3 are up 10% YTD and offer above-average yields. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot